The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial
出版年份 2020 全文链接
标题
The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type
2
diabetes mellitus: An economic evaluation using data from the
DECLARE‐TIMI 58
trial
作者
关键词
-
出版物
DIABETES OBESITY & METABOLISM
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-12-29
DOI
10.1111/dom.14308
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Assessing the cost‐effectiveness of SGLT2i in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real‐world evidence
- (2020) Phil McEwan et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin and Cardiovascular Mortality and Disease Outcomes in Type 2 Diabetes Patients Similar to the DECLARE-TIMI 58 Participants: A Nationwide Observational Study
- (2019) Anna Norhammar et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Sub-analysis From DECLARE TIMI-58 Trial
- (2019) Remo H. M. Furtado et al. CIRCULATION
- Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
- (2019) Eri T. Kato et al. CIRCULATION
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
- (2019) Hiddo J L Heerspink et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece
- (2018) George Gourzoulidis et al. CLINICAL DRUG INVESTIGATION
- DECLARE-TIMI 58: Participants’ baseline characteristics
- (2018) Itamar Raz et al. DIABETES OBESITY & METABOLISM
- Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk
- (2018) Elaine Nguyen et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting
- (2018) Abhiroop Chakravarty et al. JOURNAL OF MEDICAL ECONOMICS
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
- (2018) Vlado Perkovic et al. Lancet Diabetes & Endocrinology
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- How Representative are the Patients Included in the CV outcome Trials with SGLT2 Inhibitors of a General Type 2 Diabetes Population? A Large European Observational study
- (2018) K.I. Birkeland et al. DIABETES OBESITY & METABOLISM
- Pharmacoeconomic evaluation of sodium-glucose transporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes
- (2018) Wedad Rahman et al. EXPERT OPINION ON PHARMACOTHERAPY
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial
- (2017) David Fitchett et al. EUROPEAN HEART JOURNAL
- Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
- (2017) Yan Zheng et al. Nature Reviews Endocrinology
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
- (2017) Kåre I Birkeland et al. Lancet Diabetes & Endocrinology
- Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease
- (2017) Subodh Verma et al. CIRCULATION
- Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece
- (2016) Charalampos Tzanetakos et al. CLINICAL DRUG INVESTIGATION
- Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus
- (2016) Hui Shao et al. CURRENT MEDICAL RESEARCH AND OPINION
- Estimating the impact of better management of glycaemic control in adults with Type 1 and Type 2 diabetes on the number of clinical complications and the associated financial benefit
- (2016) M. Baxter et al. DIABETIC MEDICINE
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China
- (2016) Shuyan Gu et al. PLoS One
- Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective
- (2015) M. Charokopou et al. BMC HEALTH SERVICES RESEARCH
- Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus
- (2015) Ian J Neeland et al. Diabetes & Vascular Disease Research
- The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus
- (2015) M. Charokopou et al. DIABETIC MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries
- (2015) Ugne Sabale et al. Primary Care Diabetes
- Cost Effectiveness of Adding Dapagliflozin to Insulin for the Treatment of Type 2 Diabetes Mellitus in the Netherlands
- (2013) Heleen G. M. van Haalen et al. CLINICAL DRUG INVESTIGATION
- UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82
- (2013) A. J. Hayes et al. DIABETOLOGIA
- Cost Effectiveness of Saxagliptin and Metformin versus Sulfonylurea and Metformin in the Treatment of Type 2 Diabetes Mellitus in Germany
- (2012) Wilma Erhardt et al. CLINICAL DRUG INVESTIGATION
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The Cost-Effectiveness of Saxagliptin Versus NPH Insulin When Used in Combination with Other Oral Antidiabetes Agents in the Treatment of Type 2 Diabetes Mellitus in Poland
- (2011) Wladyslaw Grzeszczak et al. Diabetes Technology & Therapeutics
- Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden
- (2011) Ola Granström et al. Primary Care Diabetes
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More